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ABSTRACT 
Objective: A new simple, accurate, precise, economic and robust stability indicating RP-HPLC method has been developed and subsequently 
validated for the estimation of alogliptin and metformin in bulk and pharmaceutical dosage form.  
Methods: The HPLC separation was carried out by using hypersil BDS, C18 (250 x 4.6 mm, 5µ.) column with a mobile phase comprising phosphate 
buffer and acetonitrile (48:52 % v/v) pH adjusted to 4.8 with orthophosphoric acid. The flow rate of the mobile phase was 1.0 ml/min and effluent 
was monitored at 210 nm using PDA detector. The retention time of alogliptin and metformin was 3.78 min and 2.78 min respectively. Forced 
degradation studies were conducted to know the stability of the drug samples under various stress conditions like acid, base, peroxide, and 
photolytic degradation according to ICH guidelines.  
Results: The results of this study showed excellent separation of the drug samples using developed method. The percentage recoveries were found 
99.91 to 101.01% for alogliptin and 99.78-100.87% for metformin which is in the limits of acceptance. The calibration curve was plotted and the 
method was found to be linear over a range of 3-18 µg/ml and 125–750µg/ml of alogliptin and metformin respectively and regression data for 
calibration curve showed good linear relationship with r2= 0.9990 for the both alogliptin and metformin. In the study stability section, it was 
observed that there is no interference of the degradation products with drug samples. 
Conclusion: A new stability-indicating RP-HPLC method has been developed for estimation of alogliptin and metformin in bulk and pharmaceutical 
dosage form. The developed method was validated, and it was found to be simple, sensitive, precise, robust and it can be used for the routine 
analysis of alogliptin and metformin in both bulk and pharmaceutical dosage forms. 
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INTRODUCTION 
Alogliptin (ALO) is a novel hypoglycemic drug that belongs to 
dipeptidyl-peptidase-4 inhibitor class which stimulates glucose-
dependent insulin release [1-2]. Chemically, alogliptin is prepared as 
a benzoate salt, which is identified as 2-({6-[(3R)-3-aminopiperidin-
1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl} methyl) 
benzonitrile mono benzoate [fig. 1A]. It inhibits dipeptidyl peptidase 
4 (DPP-4), which normally degrades the incretins glucose-
dependent insulin tropic polypeptide (GIP) and glucagon-like 
peptide 1 [3-6]. Metformin is not chemically or pharmacologically 
related to any other classes of oral antihyperglycemic agents. 
Chemically, metformin hydrochloride [7-8] is N, N-dimethyl imido-
carbonimidic diamide hydrochloride [fig. 1B]. It has been used as the 
first-line therapy in the treatment of type 2 diabetes mellitus 
patients. Mechanism of action of metformin [9-11] is differing from 
other classes of oral hypoglycemic agents; it decreases blood glucose 
levels by decreasing hepatic glucose production and improving 
insulin sensitivity by increasing peripheral glucose uptake and 
utilization. Several analytical methods [12-17] were developed for 
alogliptin and metformin individually and also determining 
metformin simultaneously with other drug substances in combined 
dosage forms. From the thorough literature, it was thought of 
developing a new stability indicating assay method for alogliptin 
benzoate and metformin hydrochloride in combined dosage form. 
After comparing several chromatographic techniques, a reverse 
phase HPLC was selected for developing stability indicating method 
based on the physical properties of both drugs. Therefore, the 
present investigating was aimed to develop a new RP-HPLC method 
and subsequently stability studies [18-19] were conducted to know 





















Fig. 1: Chemical structure of Alogliptin (a) and Metformin (b) 
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MATERIALS AND METHODS 
Reagents and instruments 
Alogliptin and metformin were obtained as a gift sample from 
spectrum Pharma research laboratory in the hyderabad and 
marketed formulation (KAZANO, 12.5 mg alogliptine, and 500 mg 
metformin) were obtained local market. Acetonitrile, water were 
obtained from Merck. Mumbai and potassium dihydrogen 
orthophosphate, orthophosphoric acid obtained from RANKEM 
Mumbai. All solvents used in this work are HPLC grade. RP-HPLC 
waters 2695 separation module equipped with 2996 Photodiode 
Array Detector were employed in this method. Empower 2 software 
was used for LC peak integration along with data acquisition and 
data processing. The column used for the separation of analytes is 
Hypersil BDS C18 (250 x 4.6 mm, 5µ). A UV Crosslinker with a series 
of 234100 model UV chamber equipped with UV fluorescence lamp 
was used for the photolytic stability studies. 
Preparation of alogliptin (125 µg/ml) and metformin 
(5000µg/ml) standard solution 
Accurately weighed and transferred 6.25 mg of alogliptin and 50 mg 
of metformin working standards into a separate 50 ml & 10 ml clean 
dry volumetric flasks, add 7 ml of diluent to each flask then 
sonicated for 5 min and make up to the final volume with diluent. 
From the above stock solutions, 1 ml of alogliptin and metformin 
was pipetted out into a 10 ml volumetric flask and made up to 10 ml 
with diluent.  
Preparation of sample solution in tablet dosage form (Kazano 
tablets) 
20 tablets each containing alogliptin 12.5 mg and metformin 500 mg 
were powdered and calculated the average weight of each tablet. 
The tablet powder equivalent to 20 tablets was weighed and 
transferred into 50 ml volumetric flask. Add 30 ml of the diluent to 
dissolve the powder and sonicate it for about 25 min and further the 
volume was made up with diluent. From the prepared solution, 1 ml 
was pipetted out and transferred into 10 ml of volumetric flask and 
make up the volume with diluent. From the prepared solutions, 10 µl 
of the sample solution was injected into HPLC system and peak area 
response was compared with standard values and the % assay was 
calculated. The % assay was found to be 99.88%for alogliptin and 
99.64% for metformin. 
Stress degradation studies 
Forced degradation studies were performed to know the 
degradation products and to establish degradation pathway for 
alogliptin and metformin. The study involves acid hydrolysis (1 ml 
HCl heated for 30 min at 60 °) alkali hydrolysis (2N NaOH heated for 
30 min at 60 °C), oxidative degradation (20% H2O2 heated at 60 °C 
for 30 min) and thermal degradation (samples placed in oven at 105 
°C for 6 h). For photolytic stress studies, samples were exposed to 
UV light by keeping in UV chamber for 7days. 
RESULTS AND DISCUSSION 
Optimized chromatographic conditions 
The main objective of the present work is to develop and validate a 
stability indicating assay method for simultaneous estimation of 
alogliptin benzoate and metformin hydrochloride by reverse phase 
high-performance liquid chromatography. During the mobile phase 
selection, it was found that the acidic nature of the buffer could help in 
separating four drugs with good resolution. Then it was thought of 
changing pH of the buffer at different ranges like 2.5, 3.5, 4.5 & 6 to 
separate the samples. The best results were achieved with Hypersil 
BDS C18, (250 x 4.6 mm, 5µ). C18 asymmetry column with a mobile 
phase consisting of Phosphate Buffer: Acetonitrile in the ration of 
48:52 %v/v at a flow rate of 1 ml/min. Samples were analyzed at 210 
nm at an injection volume of 10 μL. The proposed method was 
optimized to give a sharp peak with minimum tailing (fig: 2). 
  
 
Fig. 2: A typical standard chromatogram of alogliptin benzoate and metformin hydrochloride 
 
Table 1: Percentage recovery studies of alogliptin and metformin 
Spiked level % Recovery Mean % recovery % RSD 
ALO MET ALO MET ALO MET 







0.326 99.79 100.37 
99.91 99.78 







0.346 101.11 100.87 
100.00 100.25 







0.194 100.24 100.18 
100.31 100.23 
ALO-Alogliptin MET-Metformin % RSD-Percentage relative standard deviation 
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The accuracy of the proposed method was established by 
determining the percentage recoveries of both the drug substances. 
Accuracy was performed for three concentrations 50%, 100% and 
150% and percentage recovery was found to be 99.79-101.11 % for 
alogliptin and 99.78-100.87 % for metformin (table 1). 
Precision 
For evaluation of precision, intraday and interday precision was 
performed at 100% concentration of alogliptin and metformin by 
injecting each three replicates. Mean average, standard deviation, 
percentage relative standard deviation were calculated and found 
within the acceptance limits (table 2).  
Linearity 
In linearity studies were performed in the range of 25-150% by 
analyzing six concentrations (n=6) of each three replicates and a 
calibration curve was plotted between concentration vs area of the 
six concentrations.  
The linearity range was determined as 3.12-18.75 µg/ml of 
alogliptin and 125-750 µg/ml of metformin and the regression value 
was calculated as 0.9990. Limit of detection (LOD) and Limit of 
quantification (LOQ) have been established by evaluating the 
minimum level at which the analyte could be readily detected and 
quantified accurately. The LOD & LOQ values was found to be 
0.0172µg/ml and 0.0521µg/ml for alogliptin and 1.218µg/ml and 
3.693µg/ml for metformin. Linearity data were given in table 3. 
Robustness 
Robustness of the proposed method was performed by changing 
conditions of the parameters such as temperature (±5 °C), mobile 
phase (±5%) and flow rate (±0.2 ml). In the robustness, no drastic 
change was observed in system suitability parameters when the 
small deliberate changes in above-mentioned parameters. 
Robustness results of the method were placed in table 4. 
Forced degradation studies 
Forced degradation studies were performed to demonstrate the 
stability of the sample. Degradation studies were carried out under 
conditions of hydrolysis, dry heat, oxidation, UV light, and 
photolysis. Acid hydrolysis was performed by treating the drug with 
2N HCl at room temperature for 24 h and it was showed little 
degradation of alogliptin and metformin with degraded products 
peak at retention time 2.362. For alkali degradation, the drug was 
treated with 2N NaOH. A chromatogram of base hydrolysis showed 
degradation of the sample with degraded product peak at retention 
time 2.295 and 3.383. Degradation studies under oxidative 
conditions were performed by heating the drug sample with 30% 
H2O2at 60 oC and degraded product peaks were observed.  
For the thermal degradation, the powdered drug was exposed to heat 
at 105 oC for 6 h. UV degradation studies were carried out for drug 
solutions by exposing solution in UV chamber at 100 watts for 7 d. In 
all the conditions, the purity of angle was found less than that of purity 
of threshold which indicates that the All the degradation samples were 
analyzed using PDA detector to monitor the purity of the peaks and 
the purity of the angle was found to be less than purity of threshold. 
Forced degradation studies were given in table 5. 
 
Table 2: Percentage assay of intraday and interday precision data 
Sample No % Assay of intraday precision % Assay of interday precision 
ALO MET ALO MET 
1 100.64 99.90 99.46 99.29 
2 100.65 99.55 101.93 99.55 
3 99.49 99.41 99.74 99.75 
4 99.81 99.97 99.79 99.56 
5 100.75 99.78 99.51 99.42 
6 99.50 99.22 99.78 98.53 
 ALO-Alogliptin MET-Metformin 
 
Table 3: Linearity data of alogliptin and metformin 
Drug name Concentration (µg/ml) Area Drug name Concentration (µg/ml) Area 
Alogliptin 3.12 70934 Metformin 125 1595665 
6.25 142300 250 3005621 
9.37 212895 375 4488605 
12.5 283908 500 6109256 
15.62 350176 625 7537189 
18.75 424958 750 9039883 
Correlation coefficient (r2) 0.9990 Correlation coefficient (r2) 0.9990 
Regression Equation Y=22571x+563.7 Regression Equation Y=12030x+28067 
 
Table 4: Robustness data of alogliptin and metformin 
Parameter Alogliptin Metformin 
RT(min) USPC TF RT(min) USPC TF 
Flow rate-0.8 ml 4.20 9100 1.20 3.09 3046 1.80 
Flow rate-1.2 ml 3.43 8709 1.20 2.54 3021 1.80 
Temperature-25 °C 3.78 9031 1.17 2.79 3799 1.64 
Temparature-35 °C 3.77 8791 1.21 2.78 3132 1.74 
Mobile Phase (-5%) 3.74 8882 1.20 2.80 3088 1.78 
Mobile Phase (+5%) 3.83 8897 1.18 2.79 3142 1.72 
RT-Retention time USPC-US Plate count TF-Tailing Factor 
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Fig. 3: Representative chromatograms of Acid (A), Base (B), Peroxide (C), Thermal (D), Photolytic (E) degradation of alogliptin and metformin 
 
Table 5: Forced degradation data 
Degradation Stress conditions % Degradation 
Alogliptin Metformin 
Acid hydrolysis 2N HCl heated at 60 °C for 30 min 7.92 7.73 
Alkali hydrolysis 2N NaOH heated at 60 °C for 30 min 6.24 6.47 
Oxidation 20% H2O2 Heated 60 °C for 30 min 5.74 5.73 
Photolytic UV chamber for 7 d 1.42 1.07 
Thermal  Oven at 105 °C for 6 h 4.52 4.47 
 
CONCLUSION 
The proposed study, a new stability-indicating RP-HPLC method has 
been developed for estimation of alogliptin benzoate and metformin 
hydrochloride in bulk and pharmaceutical dosage form. The 
developed method was validated and it was found to be simple, 
sensitive, precise, robust and it can be used for the routine analysis 
of alogliptin benzoate and metformin hydrochloride in both bulk and 
pharmaceutical dosage forms. The forced degradation studies were 
carried out in accordance with ICH guidelines, and the results 
revealed suitability of the method to study the stability of alogliptin 
benzoate and metformin hydrochloride under various degradation 
conditions like acid, base, oxidative, thermal, UV and photolytic 
degradations. Finally, it was concluded that the method is simple, 
sensitive and has the ability to separate the drug from degradation 
products and excipients found in the dosage form. 
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